Hiroshi Imazeki

Department Of Head And Neck
Tokyo, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 32 publications

Clinical role of anti-PD-1 immunotherapies in esophageal cancer.

Clinical role of anti-PD-1 immunotherapies in esophageal cancer.

Journal: Expert review of gastroenterology & hepatology

Published: March 17, 2026

FOLFOX plus nivolumab combination therapy for cisplatin-unfit patients with untreated advanced esophageal squamous cell carcinoma.

FOLFOX plus nivolumab combination therapy for cisplatin-unfit patients with untreated advanced esophageal squamous cell carcinoma.

Journal: Esophagus : official journal of the Japan Esophageal Society

Published: December 20, 2025

ANGPTL3 in the Peripheral Circulation Is Associated with Resistance to Anti-PD1 Therapy in Advanced Gastric Cancer.

ANGPTL3 in the Peripheral Circulation Is Associated with Resistance to Anti-PD1 Therapy in Advanced Gastric Cancer.

Journal: Cancer research communications

Published: December 17, 2025

Feasibility of antibiotic-assisted fecal microbiota transplantation with immunotherapy for esophageal and gastric cancer.

Feasibility of antibiotic-assisted fecal microbiota transplantation with immunotherapy for esophageal and gastric cancer.

Journal: Future oncology (London, England)

Published: December 17, 2025

Impact of Neoadjuvant Docetaxel, Cisplatin, and 5-Fluorouracil Therapy on Synchronous Early-Stage Oropharyngeal/Hypopharyngeal Cancer in Patients With Esophageal Cancer.

Impact of Neoadjuvant Docetaxel, Cisplatin, and 5-Fluorouracil Therapy on Synchronous Early-Stage Oropharyngeal/Hypopharyngeal Cancer in Patients With Esophageal Cancer.

Journal: Head & neck

Published: November 04, 2025

IL10RB expression in cancer cells is associated with evolutionary changes to solidify treatment resistance.

IL10RB expression in cancer cells is associated with evolutionary changes to solidify treatment resistance.

Journal: BJC reports

Published: October 21, 2025

Safety and short-term efficacy of neoadjuvant FLOT therapy in cisplatin-unfit patients with resectable esophageal squamous cell carcinoma.

Safety and short-term efficacy of neoadjuvant FLOT therapy in cisplatin-unfit patients with resectable esophageal squamous cell carcinoma.

Journal: Esophagus : official journal of the Japan Esophageal Society

Published: July 25, 2025

Peripheral SNCA+ cells as a poor prognostic factor for nivolumab therapy in advanced gastric cancer.

Peripheral SNCA+ cells as a poor prognostic factor for nivolumab therapy in advanced gastric cancer.

Journal: Discover oncology

Published: July 24, 2025

Real-world comparison between neoadjuvant FLOT therapy and DCF therapy for resectable esophagogastric junction adenocarcinoma.

Real-world comparison between neoadjuvant FLOT therapy and DCF therapy for resectable esophagogastric junction adenocarcinoma.

Journal: Esophagus : official journal of the Japan Esophageal Society

Published: July 15, 2025

IL33-ST2 axis is a predictive biomarker for anti-PD1 therapeutic efficacy in advanced gastric cancer.

IL33-ST2 axis is a predictive biomarker for anti-PD1 therapeutic efficacy in advanced gastric cancer.

Journal: Journal of translational medicine

Published: July 01, 2025

The FSTL1-DIP2A axis is a significant biomarker for predicting anti-PD1 therapeutic efficacy in advanced gastric cancer.

The FSTL1-DIP2A axis is a significant biomarker for predicting anti-PD1 therapeutic efficacy in advanced gastric cancer.

Journal: Cancer immunology, immunotherapy : CII

Published: June 10, 2025

The safety and short-term efficacy of nivolumab plus ipilimumab for advanced esophageal squamous cell carcinoma.

The safety and short-term efficacy of nivolumab plus ipilimumab for advanced esophageal squamous cell carcinoma.

Journal: Esophagus : official journal of the Japan Esophageal Society

Published: March 02, 2025

Showing 1-12 of 32

Last Updated: 09/26/2026